Hasil Pencarian - Vidyalakshmi Sethunath

  • Menampilkan 1 - 2 hasil dari 2
Perbaiki Hasil
  1. 1
    Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

    Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models oleh Jamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea, Tamika Mitchell, Tao Wang, Sarmistha Nanda, Resel Pereira, Robert Davis, Kristina Goutsouliak, Lanfang Qin, Carmine De Angelis, Irmina Diala, Alshad S. Lalani, Chandandeep Nagi, Susan G. Hilsenbeck, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

    High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer oleh Xiaoyong Fu, Resel Pereira, Chia-Chia Liu, Carmine De Angelis, Martin J. Shea, Sarmistha Nanda, Lanfang Qin, Tamika Mitchell, Maria L. Cataldo, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Mario Giuliano, Carolina Gutierrez, Balázs Győrffy, Meghana V. Trivedi, Ofir Cohen, Nikhil Wagle, Agostina Nardone, Rinath Jeselsohn, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: